People · Operator
Named in public records as an officer, director or promoter · active 2009–2013 · Biotechnology, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Amicus Therapeutics, Inc. | — | Biotechnology | Series D+ | $314.5M | $420.8M | 2010 |
| Dimension Therapeutics, Inc. | — | Other Technology | Series C | $94.5M | $2.0B | 2013 |
| Gloucester Pharmaceuticals Inc | — | Biotechnology | Series B | $26.0M | $806.7M | 2009 |
Donald J Hayden at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Donald J Hayden on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Donald J. Hayden, Jr. | 2 | 5 |
| Seth Harrison | 1 | 19 |
| Rishi Gupta | 1 | 12 |
| P. Sherrill Neff | 1 | 8 |
| Annalisa Jenkins | 1 | 8 |
| David Clark | 1 | 8 |
| Thomas Beck | 1 | 7 |
| David Schnell | 1 | 7 |
| Sol J. Barer | 1 | 6 |
| Ted W. Love | 1 | 5 |
| James N. Topper | 1 | 5 |
| Jay K. Hachigian | 1 | 5 |
| Thomas Dyrberg | 1 | 5 |
| Bradley Campbell | 1 | 5 |
| Jay Moorin | 1 | 4 |
| Alan B. Colowick | 1 | 3 |
| Michael A. Kelly | 1 | 3 |
| Donald Hayden | 1 | 3 |
| Martin Vogelbaum | 1 | 3 |
| John Crowley | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.